Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AJM347 in Healthy Subjects
NCT03133468Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AJM347 in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (6 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Number of participants with any adverse event at Day 15. Started Jul 2017; status: completed.
02
Drugs
AJM347
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03133468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133468.